CSL Limited (CMXHF)
OTCMKTS · Delayed Price · Currency is USD
173.50
+0.90 (0.52%)
Dec 20, 2024, 4:00 PM EST

CSL Limited Company Description

CSL Limited researches, develops, manufactures, markets, and distributes biopharmaceutical and vaccines in Australia, the United States, Germany, the United Kingdom, Switzerland, China, Hong Kong, and internationally.

The company operates through CSL Behring, CSL Seqirus, and CSL Vifor segments. The CSL Behring segment offers plasma products, gene therapies, and recombinants.

The CSL Seqirus segment provides influenza related products and pandemic services to governments. The CSL Vifor segment offers products in the therapeutic areas of iron deficiency and nephrology.

The company also licenses CSL intellectual property. CSL Limited was founded in 1916 and is headquartered in Melbourne, Australia.

CSL Limited
CSL Limited logo
Country Australia
Founded 1916
Industry Biotechnology
Sector Healthcare
Employees 32,698
CEO Paul McKenzie

Contact Details

Address:
655 Elizabeth Street
Melbourne, 3000
Australia
Phone 61 3 9389 1911
Website csl.com.au

Stock Details

Ticker Symbol CMXHF
Exchange OTCMKTS
Fiscal Year July - June
Reporting Currency USD
ISIN Number AU000000CSL8
SIC Code 2836

Key Executives

Name Position
Dr. Paul F. McKenzie Ph.D. MD, Chief Executive Officer and Executive Director
Joy Carolyn Linton B.Com., BComm, GAICD, Grad Dip AFI Interim Executive Vice President of CSL Behring
Andy Schmeltz Executive Vice President of CSL Behring Business Unit (Leave of Absence)
John A. G. Levy CPA Interim Chief Financial Officer
Chris Cooper Head of Investor Relations
Gregory Boss B.S., BS(Hons), J.D. Executive Vice President of Legal and General Counsel
Roanne Parry Chief Human Resources Officer
Dr. Andrew D. Nash BSc (Hons), GAICD, Ph.D. Senior Vice President of Research
Dr. William Mezzanotte M.D., M.P.H. Executive Vice President and Head of Research and Development
Mark Hill B.A., M.B.A. Chief Digital Information Officer and Executive Vice President